Modafinil for the Treatment of Cocaine Dependence - 1
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders
Intervention: Modafinil (Drug)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Domenic Ciraulo, M.D., Principal Investigator, Affiliation: Boston University
Summary
The purpose of this study is to evaluate the efficacy and safety of modafinil in reducing
cocaine use in subjects with cocaine dependence.
Clinical Details
Official title: Modafinil for the Treatment of Cocaine Dependence
Study design: Diagnostic, Placebo Control
Primary outcome: Cocaine abstinence
Detailed description:
This is a double-blind, placebo-controlled, parallel group design study to evaluate the
efficacy and safety of modafinil in reducing cocaine use in subjects with cocaine
dependence.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Participant must have DSM-IV diagnosis of cocaine dependence as determined by SCID.
- Must be seeking treatment for cocaine dependence.
- Must be able to understand and provide written informed consent.
Exclusion Criteria:
- Please contact the study site for more information.
Locations and Contacts
Boston University Medical Center, Boston, Massachusetts 02215, United States
New York VA Medical Center, New York, New York 10010, United States
Cincinnati Addiction Research Center, Cincinnati, Ohio 45220 2272, United States
Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania 15213 2593, United States
UTHSCSA, San Antonio, Texas 78229, United States
RHD Professional Plaza 4, Dallas, Texas 75234, United States
Additional Information
Starting date: October 2004
Ending date: December 2006
Last updated: October 23, 2007
|
